QIAGEN N.V. (QGEN)       40.9  -0.06 (-0.15%)

40.9  -0.06 (-0.15%)

NL0012169213 - Common Stock - Premarket: 40.98 +0.08 (+0.2%)


Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to QGEN. QGEN was compared to 65 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of QGEN get a neutral evaluation. Nothing too spectacular is happening here. QGEN has a valuation in line with the averages, but on the other hand it scores bad on growth




Profitability

Profitability Rating

6

QGEN's Return On Assets of 8.36% is amongst the best returns of the industry. QGEN outperforms 85% of its industry peers. The industry average Return On Assets is -8.19%.
QGEN has a Profit Margin of 22.75%. This is amongst the best returns in the industry. The industry average is -26.73%. QGEN outperforms 90% of its industry peers.

QGEN's Return On Equity of 15.67% is in line with the rest of the industry. The industry average Return On Equity is 16.52%.
QGEN has a Piotroski-F score of 6.00. This indicates an average health and profitability for QGEN.
VS Industry

ROA (8.36%) VS Industry: 85% outperformed.

-620.54
60.83

ROE (15.67%) VS Industry: 41% outperformed.

0.13
11,300.33

Profit Margin (22.75%) VS Industry: 90% outperformed.

-90,995.02
243.05

Valuation

Valuation Rating

5

QGEN's Price/Earning Ratio is a bit cheaper than the industry average which is at 24.54.
QGEN's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average industry Enterprise Value to EBITDA ratio of 16.32, QGEN is valued rather cheaply
The Price/Earnings Ratio is 15.55, which indicates a correct valuation of QGEN.

With a Forward Price/Earnings Ratio of 18.23, QGEN is valued rather expensively.
When comparing the current price to the book value of QGEN, we can conclude it is valued correctly. It is trading at 2.83 times its book value.
When comparing the price book ratio of QGEN to the average industry price book ratio of 2.30, QGEN is valued more expensive than its industry peers.
VS Industry

Price/Earnings (15.55) VS Industry: 75% outperformed.

385.00
7.69

Price/Book (2.83) VS Industry: 38% outperformed.

3,422.42
0.33

Enterprise Value/ EBITDA (11.57) VS Industry: 66% outperformed.

619.59
0.29

Growth

Growth Rating

3

QGEN shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.43% yearly.
Measured over the past 5 years, QGEN shows a quite strong growth in Revenue. The Revenue has been growing by 10.97% on average per year.
QGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.54%.
Based on estimates for the next 5 years, QGEN will show a decrease in Earnings Per Share. The EPS will decrease by -0.08% on average per year.

QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 3.27%.
QGEN is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 1.76% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS18.43% 25.52% 1.54% -14.99% -7.99% -2.45% -0.08%
Revenue10.97% 14.45% 3.27% -2.56% -1.04% 1.35% 1.76%

Health

Health Rating

4

A Current Ratio of 2.23 indicates that QGEN has no problem at all paying its short term obligations.
An Altman-Z score of 3.35 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN has a Quick Ratio of 1.89. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Altman-Z score is in line with the industry averages, which is at 2.19.

The Piotroski-F score of QGEN is 6.00. This is a neutral score and indicates average health and profitability for QGEN.
When comparing the Current Ratio of QGEN to the average industry Current Ratio of 4.84, QGEN is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 4.19, QGEN is worse placed to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of QGEN to the average industry Debt to Equity Ratio of 0.09, QGEN required more debt to finance its operations than its industry peers.
VS Industry

Debt/Equity (0.45) VS Industry: 32% outperformed.

250.82
0.00

Quick Ratio (1.89) VS Industry: 35% outperformed.

0.23
49.75

Current Ratio (2.23) VS Industry: 31% outperformed.

0.23
49.75

Altman-Z (3.35) VS Industry: 60% outperformed.

-130.46
15.29

Dividend

Dividend Rating

0

QGEN does not give a dividend.

QGEN Daily chart

QIAGEN N.V.40.9

NYSE:QGEN (9/27/2022, 7:10:51 PM)-0.06 (-0.15%)

Premarket: 40.98 +0.08 (+0.2%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 07-28 2022-07-28/bmo Earnings (Next) 11-01 2022-11-01
Ins Owners N/A Inst Owners 58.26%
Market Cap 9.29B Analysts 74
Valuation
PE 15.55 Fwd PE 18.23
PEG (NY) N/A PEG (5Y) 0.84
P/S 4.11 P/B 2.83
EV/EBITDA 11.57
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 1.54% EPS 3Y 25.52%
EPS 5Y 18.43% EPS growth Q2Q -23.88%
EPS Next Y -14.99% EPS Next 2Y -7.99%
EPS Next 3Y -2.45% EPS Next 5Y -0.08%
Revenue growth 1Y 3.27% Revenue growth 3Y 14.45%
Revenue growth 5Y 10.97% Revenue growth Q2Q -9.13%
Revenue Next Year -2.56% Revenue Next 2Y -1.04%
Revenue Next 3Y 1.35% Revenue Next 5Y 1.76%
Health
Current Ratio 2.23 Quick Ratio 1.89
Altman-Z 3.35 F-Score 6
Debt/Equity 0.45
Profitability
ROA 8.36% ROE 15.67%
ROIC 23.84% ROICg 10.36%
PM 22.75 OM 29.06
Asset Turnover 0.37

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA